TORPEdO: A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2022 Dec 1

PMID 36452431

Authors

David J Thomson

Clare Cruickshank

Helen Baines

Russell Banner

Matthew Beasley

Guy Betts

Helen Bulbeck

Frances Charlwood

Judith Christian

Matthew Clarke

Olly Donnelly

Bernadette Foran

Callum Gillies

Clare Griffin

Jarrod J Homer

Johannes A Langendijk

Lip Wai Lee

James Lester

Matthew Lowe

Andrew McPartlin

Elizabeth Miles

Christopher Nutting

Nachi Palaniappan

Robin Prestwich

James M Price

Clare Roberts

Justin Roe

Ramkumar Shanmugasundaram

Rita Simoes

Anna Thompson

Catharine West

Lorna Wilson

Jane Wolstenholme

Emma Hall

Affiliations

Soon will be listed here.

Abstract

•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

Citing Articles

Acute toxicities in proton therapy for head and neck cancer - A matched analysis of the DAHANCA 35 feasibility study.

Nowicka-Matus K, Friborg J, Hansen C, Bernsdorf M, Elstrom U, Farhadi M Clin Transl Radiat Oncol. 2024; 48:100835.

PMID: 39189000 PMC: 11345689. DOI: 10.1016/j.ctro.2024.100835.

Impact of Relative Biologic Effectiveness for Proton Therapy for Head and Neck and Skull-Base Tumors: A Technical and Clinical Review.

Holtzman A, Mohammadi H, Furutani K, Koffler D, McGee L, Lester S Cancers (Basel). 2024; 16(11).

PMID: 38893068 PMC: 11171304. DOI: 10.3390/cancers16111947.

Equality, diversity, and inclusion in oncology clinical trials: an audit of essential documents and data collection against INCLUDE under-served groups in a UK academic trial setting.

Patel D, Kilburn L, Fox L, Hall E, Bliss J, Lewis R BMC Med Ethics. 2023; 24(1):105.

PMID: 38017503 PMC: 10685485. DOI: 10.1186/s12910-023-00987-w.

Failure patterns of locoregional recurrence after reducing target volumes in patients with nasopharyngeal carcinoma receiving adaptive replanning during intensity-modulated radiotherapy: a single-center experience in China.

Zhou X, Zhu J, Zhou C, Wang W, Ding W, Chen M Radiat Oncol. 2023; 18(1):190.

PMID: 37974274 PMC: 10652536. DOI: 10.1186/s13014-023-02373-7.

A Retrospective Comparison of Toxicity, Response and Survival of Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiation Therapy in the Treatment of Rectal Carcinoma.

Kouklidis G, Nikolopoulos M, Ahmed O, Eskander B, Masters B Cureus. 2023; 15(11):e48128.

PMID: 37929269 PMC: 10620340. DOI: 10.7759/cureus.48128.

References

Patterson J, Hildreth A, McColl E, Carding P, Hamilton D, Wilson J . The clinical application of the 100mL water swallow test in head and neck cancer. Oral Oncol. 2011; 47(3):180-4. DOI: 10.1016/j.oraloncology.2010.11.020. View

Ofuya M, McParland L, Murray L, Brown S, Sebag-Montefiore D, Hall E . Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy. Clin Transl Radiat Oncol. 2019; 19:17-26. PMC: 6660607. DOI: 10.1016/j.ctro.2019.07.002. View

Roe J, Drinnan M, Carding P, Harrington K, Nutting C . Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia?. Oral Oncol. 2014; 50(12):1182-7. DOI: 10.1016/j.oraloncology.2014.09.009. View

Nutting C, Morden J, Harrington K, Urbano T, Bhide S, Clark C . Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2):127-36. PMC: 3033533. DOI: 10.1016/S1470-2045(10)70290-4. View

Blanchard P, Garden A, Gunn G, Rosenthal D, Morrison W, Hernandez M . Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol. 2016; 120(1):48-55. PMC: 5474304. DOI: 10.1016/j.radonc.2016.05.022. View

Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, Homer J . Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S90-S96. PMC: 4873902. DOI: 10.1017/S0022215116000505. View

Crellin A . The Road Map for National Health Service Proton Beam Therapy. Clin Oncol (R Coll Radiol). 2018; 30(5):277-279. DOI: 10.1016/j.clon.2018.02.032. View

Zietman A . Too Big to Fail? The Current Status of Proton Therapy in the USA. Clin Oncol (R Coll Radiol). 2017; 30(5):271-273. DOI: 10.1016/j.clon.2017.11.002. View

List M, Lansky S . A performance status scale for head and neck cancer patients. Cancer. 1990; 66(3):564-9. DOI: 10.1002/1097-0142(19900801)66:3<564::aid-cncr2820660326>3.0.co;2-d. View

10.

Langendijk J, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M . Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013; 107(3):267-73. DOI: 10.1016/j.radonc.2013.05.007. View

11.

. Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit. Clin Oncol (R Coll Radiol). 2018; 30(5):280-284. DOI: 10.1016/j.clon.2018.02.031. View

12.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

13.

Rwigema J, Langendijk J, van der Laan H, Lukens J, Swisher-McClure S, Lin A . A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2019; 104(3):553-562. DOI: 10.1016/j.ijrobp.2018.12.055. View

14.

Wopken K, Bijl H, Langendijk J . Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature. Radiother Oncol. 2017; 126(1):56-67. DOI: 10.1016/j.radonc.2017.08.022. View

15.

Langendijk J, Doornaert P, Verdonck-de Leeuw I, Leemans C, Aaronson N, Slotman B . Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008; 26(22):3770-6. DOI: 10.1200/JCO.2007.14.6647. View

16.

Price J, Hall E, West C, Thomson D . TORPEdO - A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer. Clin Oncol (R Coll Radiol). 2019; 32(2):84-88. DOI: 10.1016/j.clon.2019.09.052. View